Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Compass Therapeutics (CMPX)
NASDAQ:CMPX
RESEARCH TOOLSreports
Holding CMPX?
Track your performance easily
CMPX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.77 - $2.34
Previous Close$1.79
Volume211.44K
Average Volume (3M)453.05K
Market Cap
$233.90M
Enterprise Value$117.76M
Total Cash (Recent Filing)$135.40M
Total Debt (Recent Filing)$6.88M
Price to Earnings (P/E)―
Beta1.41
Next Earnings
Mar 19, 2025EPS Estimate
-$0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.35
Shares Outstanding137,589,171
10 Day Avg. Volume520,247
30 Day Avg. Volume453,051
Standard Deviation0.27
R-Squared0.02
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)1.69
Price to Sales (P/S)307.55
Price to Cash Flow (P/CF)-6.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue138.54
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-2.30
Forecast
1Y Price Target
$8.75Price Target Upside414.71% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Compass Therapeutics News
PremiumCompany Announcements
Compass Therapeutics Reports Q3 2024 Financials and Clinical Progress
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentCTX-471, even as a monotherapy agent, has promising anti-tumor activity in patients with advanced solid tumors who currently have limited treatment options.
Financial PerformanceCompass posted a better-than-expected EPS of ($0.08), compared with an estimate of ($0.11), indicating stronger financial performance than anticipated.
Financial PositionThe company ended the quarter with $135 million, which management expects to provide runway into 1Q27, highlighting a strong financial position.
Bears Say
Clinical TrialsCMPX will not continue to stage 2 of the simon 2-stage COMPANION-003 trial, and will instead evaluate CTX-009 + chemo in 2L DLL4+ CRC.
Price Target AdjustmentThe net of our changes brings our PT to $5 (from $10).
Safety ConcernsThe CTX-471 (CD137; 4-1BB) + pembro Phase 1b trial will be discontinued due to safety concerns.
---
Ownership Overview
20.70% Insiders
5.31% Mutual Funds
0.82% Other Institutional Investors
67.06% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
CMPX FAQ
What was Compass Therapeutics’s price range in the past 12 months?
Compass Therapeutics lowest stock price was $0.77 and its highest was $2.34 in the past 12 months.
What is Compass Therapeutics’s market cap?
Currently, no data Available
When is Compass Therapeutics’s upcoming earnings report date?
Compass Therapeutics’s upcoming earnings report date is Mar 19, 2025 which is in 125 days.
How were Compass Therapeutics’s earnings last quarter?
Compass Therapeutics released its earnings results on Nov 12, 2024. The company reported -$0.08 earnings per share for the quarter, beating the consensus estimate of -$0.113 by $0.033.
Is Compass Therapeutics overvalued?
According to Wall Street analysts Compass Therapeutics’s price is currently Undervalued.
Does Compass Therapeutics pay dividends?
Compass Therapeutics does not currently pay dividends.
What is Compass Therapeutics’s EPS estimate?
Compass Therapeutics’s EPS estimate is -$0.11.
How many shares outstanding does Compass Therapeutics have?
Compass Therapeutics has 137,589,170 shares outstanding.
What happened to Compass Therapeutics’s price movement after its last earnings report?
Compass Therapeutics reported an EPS of -$0.08 in its last earnings report, beating expectations of -$0.113. Following the earnings report the stock price went down -5.789%.
Which hedge fund is a major shareholder of Compass Therapeutics?
Among the largest hedge funds holding Compass Therapeutics’s share is Blackstone Inc.. It holds Compass Therapeutics’s shares valued at 8M.
---
Compass Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.75 (414.71% Upside)
$8.75 (414.71% Upside)
Hedge Fund Trend
Increased
By 1.5M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.9%
Last 30 Days ▲ 1.6%
Last 30 Days ▲ 1.6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
15.48%
12-Months-Change
Fundamentals
Return on Equity
-32.01%
Trailing 12-Months
Asset Growth
-12.28%
Trailing 12-Months
Company Description
Compass Therapeutics
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is developing proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies. Its pipeline product candidates are CTX-471/ CD137 agonist and CTX-8371.
---
CMPX Stock 12 Month Forecast
Average Price Target
$8.75
▲(414.71% Upside)
Technical Analysis
Adaptimmune Therapeutics
―
Kiniksa Pharmaceuticals
―
Fate Therapeutics
―
Meiragtx Holdings
―
Best Analysts Covering CMPX
1 Year
1 Year Success Rate
6/9 ratings generated profit
1 Year Average Return
+8.92%
reiterated a buy rating 2 days ago
Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +8.92% per trade.
---